Form 8-K - Current report:
SEC Accession No. 0001140361-25-024413
Filing Date
2025-07-02
Accepted
2025-07-01 17:42:25
Documents
12
Period of Report
2025-06-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K ef20051467_8k.htm   iXBRL 8-K 32702
  Complete submission text file 0001140361-25-024413.txt   161653

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bbio-20250627.xsd EX-101.SCH 3868
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20250627_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20250627_pre.xml EX-101.PRE 16046
14 EXTRACTED XBRL INSTANCE DOCUMENT ef20051467_8k_htm.xml XML 4224
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 251097599
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)